Literature DB >> 31655118

The mutational landscape of mucosal melanoma.

Kelsey W Nassar1, Aik Choon Tan2.   

Abstract

Mucosal melanoma is a rare and aggressive subtype of melanoma that has a less favorable prognosis due to the lack of understanding and identification of oncogenic drivers. Recently, whole genome and whole exome sequencing have unveiled the molecular landscape and potential oncogenic drivers of mucosal melanoma, which remains distinct from cutaneous melanoma. In this review, we provide an overview of the genomic landscape of mucosal melanoma, with a focus on molecular studies identifying potential oncogenic drivers allowing for a better mechanistic understanding of the biology of mucosal melanoma. We summarized the published genomics and clinical data supporting the observations that mucosal melanoma harbors distinct genetic alterations and oncogenic drivers from cutaneous melanoma, and thus should be treated accordingly. The common drivers (BRAF and NRAS) found in cutaneous melanoma have lower mutation rate in mucosal melanoma. In contrast, SF3B1 and KIT have higher mutation rate in mucosal melanoma as compared to cutaneous melanoma. From the meta-analysis, we also observed that the mutational profiles are slightly different between the "upper" and "lower" regions of mucosal melanoma, providing new insights and therapeutic options for the mucosal melanoma patients. Mutations identified in mucosal melanoma should be incorporated into routine clinical testing, as there are targeted therapies already developed for treating patients with these mutations in the precision medicine era.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Druggable targets; KIT; Mucosal melanoma; Mutational landscape; SF3B1

Mesh:

Substances:

Year:  2019        PMID: 31655118      PMCID: PMC7078020          DOI: 10.1016/j.semcancer.2019.09.013

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  112 in total

1.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

2.  Sunitinib therapy for melanoma patients with KIT mutations.

Authors:  David R Minor; Mohammed Kashani-Sabet; Maria Garrido; Steven J O'Day; Omid Hamid; Boris C Bastian
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

3.  BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.

Authors:  Atul Kulkarni; Husam Al-Hraishawi; Srilatha Simhadri; Kim M Hirshfield; Suzie Chen; Sharon Pine; Chandrika Jeyamohan; Levi Sokol; Siraj Ali; Man Lung Teo; Eileen White; Lorna Rodriguez-Rodriguez; Janice M Mehnert; Shridar Ganesan
Journal:  Clin Cancer Res       Date:  2017-05-24       Impact factor: 12.531

4.  KIT pathway alterations in mucosal melanomas of the vulva and other sites.

Authors:  Katarina Omholt; Eva Grafström; Lena Kanter-Lewensohn; Johan Hansson; Boel K Ragnarsson-Olding
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

5.  Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations.

Authors:  Rong Zhou; Chaoji Shi; Wenjie Tao; Jiang Li; Jing Wu; Yong Han; Guizhu Yang; Ziyue Gu; Shengming Xu; Yujue Wang; Lizhen Wang; Yanan Wang; Guoyu Zhou; Chenping Zhang; Zhiyuan Zhang; Shuyang Sun
Journal:  Clin Cancer Res       Date:  2019-02-19       Impact factor: 12.531

6.  KIT gene mutations and copy number in melanoma subtypes.

Authors:  Carol Beadling; Erick Jacobson-Dunlop; F Stephen Hodi; Claudia Le; Andrea Warrick; Janice Patterson; Ajia Town; Amy Harlow; Frank Cruz; Sharl Azar; Brian P Rubin; Susan Muller; Rob West; Michael C Heinrich; Christopher L Corless
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.

Authors:  D Handolias; A L Hamilton; R Salemi; A Tan; K Moodie; L Kerr; A Dobrovic; G A McArthur
Journal:  Br J Cancer       Date:  2010-04-06       Impact factor: 7.640

8.  Low mutational burden of eight genes involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 pathways in female genital tract primary melanomas.

Authors:  Kalliopi I Pappa; George D Vlachos; Maria Roubelakis; Dimitrios-Efthymios G Vlachos; Theodora G Kalafati; Dimitrios Loutradis; Nicholas P Anagnou
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

9.  The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China.

Authors:  Xuhui Ma; Yunteng Wu; Tian Zhang; Hao Song; Houyu Jv; Wei Guo; Guoxin Ren
Journal:  Oncotarget       Date:  2017-07-31

10.  KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.

Authors:  A Zebary; M Jangard; K Omholt; B Ragnarsson-Olding; J Hansson
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

View more
  31 in total

Review 1.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

2.  Identification of RPL5 gene variants and the risk of hepatic vein thrombosis in Saudi patients.

Authors:  Fathelrahman M Hassan; Afnan A Alsultan; Faisal Alzahrani; Waleed H Albuali; Dalal K Bubshait; Elfadil M Abass; Mudathir A Elbasheer; Abdulmohsen A Alkhanbashi
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

3.  Adamantinoma-Like Ewing Sarcoma of the Head and Neck: A Case-Series of a Rare and Challenging Diagnosis.

Authors:  Munita Bal; Aekta Shah; Bharat Rekhi; Neha Mittal; Swapnil Ulhas Rane; Katha Rabade; Omshree Shetty; Gouri Pantavaidya; Deepa Nair; Kumar Prabhash; M Aishwarya; Krishan Kumar Govindarajan; Siddhartha Laskar; Sarbani Ghosh Laskar; Asawari Patil
Journal:  Head Neck Pathol       Date:  2022-01-13

Review 4.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: The Neck and Lymph Nodes, Metastasis, and Melanocytic Tumors.

Authors:  Juan C Hernandez-Prera
Journal:  Head Neck Pathol       Date:  2022-03-21

5.  Association between VDR Gene Polymorphisms and Melanoma Susceptibility in a Colombian Population.

Authors:  Andres Felipe Aristizabal-Pachon; Yeimy Gonzalez-Giraldo; Angela Yazmin Garcia; Dalia Xiomara Suarez; Angela Rodriguez; Janneth Gonzalez-Santos
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

6.  Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.

Authors:  Olivia Beaudoux; Marine Ehret; Emilie Criquet; Joséphine Franceschi; Anne Durlach; Jean-Bapstiste Oudart; Laetitia Visseaux; Florent Grange
Journal:  Acta Derm Venereol       Date:  2021-04-12       Impact factor: 3.875

7.  Genetic alteration of Chinese patients with rectal mucosal melanoma.

Authors:  Huan Li; Lujing Yang; Yumei Lai; Xintong Wang; Xinyin Han; Siyao Liu; Dongliang Wang; Xiaojuan Li; Nana Hu; Yan Kong; Lu Si; Zhongwu Li
Journal:  BMC Cancer       Date:  2021-05-27       Impact factor: 4.430

Review 8.  Current Status and Prospects of Immunotherapy for Gynecologic Melanoma.

Authors:  Mayuka Anko; Yusuke Kobayashi; Kouji Banno; Daisuke Aoki
Journal:  J Pers Med       Date:  2021-05-12

Review 9.  Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas.

Authors:  Jiri Vachtenheim; Lubica Ondrušová
Journal:  Life (Basel)       Date:  2021-05-05

Review 10.  Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.

Authors:  Anna Han; Zachary T Schug; Andrew E Aplin
Journal:  Trends Cancer       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.